ArticleCureus2025
Real-Time Motion Management for a Small Target in the Right Lower Lobe With Large Tumor Motion Using Radixact Synchrony: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of tumor size on motion tracking and dosimetric accuracy using Radixact Synchrony.Journal of radiation research · 2026Article
- Markerless tumor tracking for lung SBRT with the Radixact Synchrony system: Initial experience and short-term clinical outcomes.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate real-time motion tracking is crucial for effective stereotactic body radiotherapy (SBRT) in lung cancer patients, particularly those with significant tumor motion. Techniques to reduce tumor motion, such as abdominal compression, breath hold, or respiratory gating, are often uncomfortable or result in longer treatment times. The Radixact Synchrony system (Accuray Inc., Sunnyvale, California, United States) enables continuous adaptation to tumor motion without the need for implanted fiducials. We report the case of a patient with a small target in the right lower lobe (RLL) with large tumor motion managed using Radixact Synchrony, highlighting treatment planning, delivery accuracy, and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.